DxDiscovery: A Reno-based biotech firm specializing in developing microbial monoclonal antibodies for disease prevention, treatment, and rapid diagnostics.
Founded in Reno, DxDiscovery is a biotechnology research and development company with a core mission to create high-quality, high-affinity microbial monoclonal antibodies. These antibodies are designed for use in rapid point-of-care diagnostics and as prophylactics or therapeutics for infectious diseases. The company's products aim to address the limitations of current diagnostic methods, which can be time-consuming or prone to inaccuracies.
DxDiscovery has attracted notable experts and investors in the biotech field, contributing to its innovative advancements. The company has achieved significant milestones in developing effective diagnostics and treatments, enhancing the speed and accuracy of disease detection and prevention. Its impact is evident in the improved healthcare outcomes facilitated by its cutting-edge antibody technologies.
